ArticleCancer discovery2021
A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS-Driven Lung Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
7.3field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- A multiplexed in vivo approach to identify driver genes in small cell lung cancer.Cell reports · 2023Pooled it
- Tumor suppressor genotype influences the extent and mode of immunosurveillance in lung cancer.Nature communications · 2026Article
- Article
- EML4-ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis.Cancer discovery · 2026Article
- Experimental evolution in an era of molecular manipulation.Nature reviews. Genetics · 2026Review
- Functional Mapping of Epigenomic Regulators Uncovers Coordinated Tumor Suppression by the HBO1 and MLL1 Complexes.Cancer discovery · 2025Article
- The repressor Capicua is a barrier to lung tumor development driven by Kras/Trp53 mutations.EMBO molecular medicine · 2025Article
- Mutation of CMTR2 in Lung Adenocarcinoma Alters RNA Alternative Splicing and Reveals Therapeutic Vulnerabilities.Nature communications · 2025Article
- Efficient and multiplexed somatic genome editing with Cas12a mice.Nature biomedical engineering · 2025Article
- Integrative multiomic approaches reveal ZMAT3 and p21 as conserved hubs in the p53 tumor suppression network.Cell death and differentiation · 2025Article
- Aging represses oncogenic KRAS-driven lung tumorigenesis and alters tumor suppression.Nature aging · 2025Article
- RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma.Cancer research · 2025Article
- Combinatorial In Vivo Genome Editing Identifies Widespread Epistasis and an Accessible Fitness Landscape During Lung Tumorigenesis.Molecular biology and evolution · 2025Article
- Emerging roles of cohesin-STAG2 in cancer.Oncogene · 2025Review
- A STAG2-PAXIP1/PAGR1 axis suppresses lung tumorigenesis.The Journal of experimental medicine · 2025Article
- Kelch-like ECH-associated Protein 1/Nuclear Factor Erythroid 2-related Factor 2 Pathway and Its Interplay with Oncogenes in Lung Tumorigenesis.Journal of cancer prevention · 2024Review
- Gene-based burden tests of rare germline variants identify six cancer susceptibility genes.Nature genetics · 2024Article
- How CRISPR Is Revolutionizing the Generation of New Models for Cancer Research.Cold Spring Harbor perspectives in medicine · 2024Review
- Regulation of antioxidants in cancer.Molecular cell · 2024Review
- Oncogenic context shapes the fitness landscape of tumor suppression.Nature communications · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 4 institutions in 2 countries.
Hongchen Cai *Department of Genetics, Stanford University School of Medicine, Stanford, California.
Su Kit Chew *Cancer Evolution and Genome Instability Laboratory, University College London Cancer Institute, London, United Kingdom.
Chuan Li *Department of Biology, Stanford University, Stanford, California.ORCID 0000-0002-4381-3891
Min K TsaiDepartment of Genetics, Stanford University School of Medicine, Stanford, California.ORCID 0000-0003-4732-4259
Laura AndrejkaDepartment of Genetics, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-2202-5626
Christopher W MurrayCancer Biology Program, Stanford University School of Medicine, Stanford, California.
Nicholas W HughesDepartment of Genetics, Stanford University School of Medicine, Stanford, California.
Emily G ShuldinerDepartment of Biology, Stanford University, Stanford, California.
Emily L AshkinCancer Biology Program, Stanford University School of Medicine, Stanford, California.
Rui TangDepartment of Genetics, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-6950-9580
King L HungCancer Biology Program, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-3662-4662
Leo C ChenDepartment of Genetics, Stanford University School of Medicine, Stanford, California.
Shi Ya C LeeCancer Evolution and Genome Instability Laboratory, University College London Cancer Institute, London, United Kingdom.ORCID 0000-0003-1715-2265
Maryam YousefiDepartment of Genetics, Stanford University School of Medicine, Stanford, California.
Wen-Yang LinDepartment of Genetics, Stanford University School of Medicine, Stanford, California.
Christian A KunderDepartment of Pathology, Stanford University School of Medicine, Stanford, California.ORCID 0000-0003-1514-7550
Le CongDepartment of Genetics, Stanford University School of Medicine, Stanford, California.
Christopher D McFarlandDepartment of Biology, Stanford University, Stanford, California.
Dmitri A PetrovDepartment of Biology, Stanford University, Stanford, California. mwinslow@stanford.edu Charles.Swanton@crick.ac.uk dpetrov@stanford.edu.
Charles SwantonCancer Evolution and Genome Instability Laboratory, University College London Cancer Institute, London, United Kingdom. mwinslow@stanford.edu Charles.Swanton@crick.ac.uk dpetrov@stanford.edu.ORCID 0000-0002-4299-3018
Monte M WinslowDepartment of Genetics, Stanford University School of Medicine, Stanford, California. mwinslow@stanford.edu Charles.Swanton@crick.ac.uk dpetrov@stanford.edu.
Stanford University · USStanford Medicine · USCRUK Lung Cancer Centre of Excellence · GBThe Francis Crick Institute · GB
Funding
Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Melinda L. Telli · 2007 to 2026
$71.4MINSTITUTIONAL TRAINING GRANT IN GENOME SCIENCET32HG000044 · NHGRI · STANFORD UNIVERSITY · PI MICHAEL P. SNYDER · 1995 to 2026
$32.2MLeveraging innovative technologies in basic and clinical cancer researchT32CA009302 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI, Aaron M Newman · 1985 to 2026
$19.1MGenomics of rapid adaptation in the lab and in the wildR35GM118165 · NIGMS · STANFORD UNIVERSITY · PI Dmitri Petrov · 2016 to 2026
$8.3MTowards Robust Multiplex Genome Engineering Beyond CRISPR-Cas9R35HG011316 · NHGRI · STANFORD UNIVERSITY · PI CONG, LE · 2020 to 2025
$2.8MUnraveling mechanisms of tumor suppression in lung cancerR01CA234349 · NCI · STANFORD UNIVERSITY · PI PETROV, DMITRI, WINSLOW, MONTE MEIER · 2019 to 2023
$2.4M(PQ4) Quantitative and multiplexed analysis of gene function in cancer in vivoR01CA231253 · NCI · STANFORD UNIVERSITY · PI PETROV, DMITRI, WINSLOW, MONTE MEIER · 2018 to 2022
$2.3MMolecular dissection of Lkb1-mediated tumor suppressionR01CA230919 · NCI · STANFORD UNIVERSITY · PI WINSLOW, MONTE MEIER · 2018 to 2022
$2.1MA Quantitative Multiplexed Platform for the Pharmacogenomic Analysis of Lung CancerR01CA207133 · NCI · STANFORD UNIVERSITY · PI PETROV, DMITRI, WINSLOW, MONTE MEIER · 2016 to 2018
$1.7MQuantifying the sources and dynamics of tumor growth variability using Tuba-seqR00CA226506 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MCFARLAND, CHRISTOPHER DENNIS · 2021 to 2023
$747kQuantifying the sources and dynamics of tumor growth variability using Tuba-seqK99CA226506 · NCI · STANFORD UNIVERSITY · PI MCFARLAND, CHRISTOPHER DENNIS · 2018 to 2019
$202kTherapeutic dissection of genotype-specific lung cancer vulnerabilitiesF32CA236311 · NCI · STANFORD UNIVERSITY · PI YOUSEFI, MARYAM · 2019 to 2021
$169kCancer Research UK 17786Cancer Research UK 20466Cancer Research UK 25253Cancer Research UK 30025Cancer Research UK FC001169Medical Research Council FC001169NCI NIH HHS F32 CA236311NCI NIH HHS K99 CA226506NCI NIH HHS P30 CA124435NCI NIH HHS R00 CA226506NCI NIH HHS R01 CA207133NCI NIH HHS R01 CA230919NCI NIH HHS R01 CA231253NCI NIH HHS R01 CA234349NCI NIH HHS T32 CA009302NHGRI NIH HHS R35 HG011316NHGRI NIH HHS T32 HG000044NIGMS NIH HHS R35 GM118165Wellcome Trust FC001169
Abstract
Cancer genotyping has identified a large number of putative tumor suppressor genes. Carcinogenesis is a multistep process, but the importance and specific roles of many of these genes during tumor initiation, growth, and progression remain unknown. Here we use a multiplexed mouse model of oncogenic KRAS-driven lung cancer to quantify the impact of 48 known and putative tumor suppressor genes on diverse aspects of carcinogenesis at an unprecedented scale and resolution. We uncover many previously understudied functional tumor suppressors that constrain cancer
Indexed as
Genes, Tumor SuppressorCell Transformation, NeoplasticHumansLung NeoplasmsProto-Oncogene Proteins p21(ras)Proto-Oncogene Proteins p21(ras)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.